Latest research and explainers from Peptides.
May 4, 2026
KPV is a small peptide fragment of alpha-MSH that shows promise in gut inflammation science. With significant interest driven by its unique mechanism and demand in the peptide market, its clinical application remains largely unproven, requiring further research and caution in use.
May 4, 2026
This article examines the disproportionate representation of women in clinical trials related to GLP-1 drugs. Despite women being the majority responders in trials, the protocols for these medications have largely been developed with male users in mind. The article calls for a reevaluation of these protocols to consider female physiology and hormonal contexts in peptide therapies.
April 29, 2026
The article discusses a new peptide-drug conjugate, GLP-1–GIP–Lani, which activates five different receptors simultaneously and has shown significant results in preclinical studies in mice, outperforming existing obesity drugs.
April 18, 2026
A thorough exploration of the changing landscape in obesity treatment as new peptides emerge, highlighting the limitations of current therapies like Ozempic and presenting a more personalized, targeted approach to obesity management with emerging drug candidates.
April 4, 2026
This article discusses the four leading peptides—BPC-157, TB-500, GHK-Cu, and Thymosin Beta-4—that show the most promise for aiding recovery and healing processes in the body, detailing their mechanisms, effectiveness, limitations, and protocols for use.
April 4, 2026
Navigating the peptide market in 2026 involves understanding the shifted dynamics of peptide providers and adhering to a systematic evaluation framework to ensure safety and legitimacy in sourcing peptides.
April 4, 2026
This article explores the impact of genetic variations on individual responses to peptide therapies, highlighting how genetics can influence receptor sensitivity, metabolism, and overall efficacy, thus challenging the one-size-fits-all approach to peptide protocols.
April 4, 2026
Peptide stacking is a common practice that combines various peptides for enhanced effects. This guide explores the rationale behind popular stacks, the evidence supporting them, and various protocols for specific goals. Despite anecdotal reports of success, the lack of clinical validation highlights the importance of understanding each compound's mechanism and possible outcomes.
March 29, 2026
This article examines the discrepancies in the peptide and genetics market, revealing the lack of substantial genetic testing and outcome data in peptide therapy.
March 15, 2026
A data scientist utilized AI tools, including ChatGPT and AlphaFold, to develop a personalized mRNA vaccine for his dog diagnosed with terminal cancer, achieving significant tumor reduction without a biology degree.
March 12, 2026
Two weeks after RFK Jr.'s announcement regarding the restoration of access to certain peptides, no formal actions have been taken by the FDA, leaving regulatory and patient access in limbo.
March 10, 2026
This article provides a detailed examination of the legal avenues through which individuals can access semaglutide and tirzepatide, highlighting cost variances between direct purchases, telehealth options, and insurance coverage.
